KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Non-Current Liabilities: 2010-2025

Historic Total Non-Current Liabilities for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $211.2 million.

  • Nektar Therapeutics' Total Non-Current Liabilities fell 16.23% to $211.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $211.2 million, marking a year-over-year decrease of 16.23%. This contributed to the annual value of $235.9 million for FY2024, which is 10.11% down from last year.
  • As of Q3 2025, Nektar Therapeutics' Total Non-Current Liabilities stood at $211.2 million, which was down 6.58% from $226.1 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Total Non-Current Liabilities registered a high of $457.5 million during Q1 2021, and its lowest value of $211.2 million during Q3 2025.
  • Over the past 3 years, Nektar Therapeutics' median Total Non-Current Liabilities value was $255.6 million (recorded in 2024), while the average stood at $257.1 million.
  • Per our database at Business Quant, Nektar Therapeutics' Total Non-Current Liabilities skyrocketed by 35.86% in 2021 and then fell by 27.17% in 2023.
  • Nektar Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $410.0 million in 2021, then dropped by 17.94% to $336.4 million in 2022, then declined by 22.00% to $262.4 million in 2023, then declined by 10.11% to $235.9 million in 2024, then fell by 16.23% to $211.2 million in 2025.
  • Its Total Non-Current Liabilities was $211.2 million in Q3 2025, compared to $226.1 million in Q2 2025 and $235.7 million in Q1 2025.